Introduction
============

Lung cancer has emerged as the most common malignant tumor and accounts for \~25% of cancer-associated mortalities worldwide according to the latest cancer statistics report ([@b1-ol-0-0-10905]). The main pathological types of lung cancer include small cell lung cancer and non-small cell lung cancer, the latter of which predominantly comprising of lung adenocarcinoma (LUAD) cases ([@b2-ol-0-0-10905]). Despite advances in diagnostic tools, surgical approaches and chemotherapy, the 5-year survival rate of patients with lung cancer is reported to be \<10%, potentially due to the lack of effective biomarkers ([@b3-ol-0-0-10905],[@b4-ol-0-0-10905]). Therefore, the identification of novel and reliable diagnostic and prognostic biomarkers is required.

The human brain-expressed X-linked (BEX) family consists of five members, BEX1-5, located on the Xq22 chromosome ([@b5-ol-0-0-10905]). Members of the BEX family are widely expressed in several types of tissues, and are closely associated with the development of neurons ([@b6-ol-0-0-10905]). Previous studies have demonstrated that BEX members play important roles in regulating important cellular processes, including the cell cycle and apoptosis ([@b7-ol-0-0-10905]--[@b9-ol-0-0-10905]). Increasing evidence revealed that BEX members are aberrantly expressed in different types of cancer, suggesting that they may serve roles in tumorigenesis ([@b10-ol-0-0-10905]--[@b22-ol-0-0-10905]). BEX1 is implicated in leukemogenesis, and aberrant downregulation of BEX1 has been observed in acute and chronic myeloid leukemia ([@b10-ol-0-0-10905],[@b11-ol-0-0-10905]). Furthermore, BEX1 is associated with the development of other types of cancer, including pediatric intracranial ependymoma and esophageal squamous cell cancer ([@b12-ol-0-0-10905],[@b13-ol-0-0-10905]). BEX2 may serve as an oncogene in different types of cancer, including glioma, breast and colorectal cancer ([@b14-ol-0-0-10905]--[@b16-ol-0-0-10905]). By contrast, BEX3 inhibits the formation of breast tumors and serves a pro-apoptotic role ([@b17-ol-0-0-10905],[@b18-ol-0-0-10905]). Previous studies revealed that BEX4 serves as a tumor suppressor in ovarian cancer and as an oncogene in oral squamous cell carcinoma ([@b19-ol-0-0-10905],[@b20-ol-0-0-10905]). To the best of the authors\' knowledge, the role of BEX5 in cancer remains unreported. The aforementioned studies highlighted an association between the BEX family and various types of cancer. However, few studies have investigated the association between the BEX family and lung cancer. A previous study reported that high expression levels of BEX2 and BEX4 were significantly associated with a favorable prognosis in patients with LUAD ([@b21-ol-0-0-10905]). Furthermore, overexpression of BEX4 may promote LUAD cell proliferation and growth *in vitro* ([@b22-ol-0-0-10905]). The potential significance of the BEX family in LUAD therefore warrants further investigation.

The present study investigated the specific expression patterns of BEX members as well as their clinical significance in LUAD by mining databases and performing *in vitro* experiments. The results obtained in the present study revealed that the BEX family was downregulated in LUAD samples and tumor cell lines compared with normal samples and human bronchial epithelial cells, respectively, and may be involved in LUAD pathogenesis. The association between the expression levels of BEX members and the clinicopathological parameters of patients with LUAD was therefore further investigated and the diagnostic and prognostic values of the BEX family in patients with LUAD were assessed.

Materials and methods
=====================

### Data mining

Publicly available LUAD gene expression data and the corresponding The Cancer Genome Atlas (TCGA; [cancergenome.nih.gov/](cancergenome.nih.gov/)) clinical data were obtained from the University of California Santa Cruz Xena repository ([xenabrowser.net](xenabrowser.net)). The expression data was obtained from the files entitled 'TCGA_LUAD_sampleMap/HiSeqV2/PANCAN'. Additionally, the clinical phenotype information was selected from 'TCGA_LUAD_sampleMap/LUAD_clinicalMatrix'. Based on the criteria, the gene expression data from the TCGA was transformed by log2(x+1) and normalized across all cohorts, then extracted and matched with the clinical data as reported in ([@b23-ol-0-0-10905]).

A total of 574 cases (515 LUAD samples and 59 normal samples from heathy controls) with BEX family expression data and 482 LUAD samples with gene expression data and clinicopathological information were included in the current study. In order to investigate the expression levels of BEX members in clinical LUAD samples, a cohort of 59 pairs of LUAD and adjacent non-cancerous tissues were taken from the 574 LUAD cases. The cancer samples were staged according to the American Joint Committee on Cancer staging system ([@b24-ol-0-0-10905]).

The mRNA expression of BEX members in LUAD was investigated using the Oncomine database ([oncomine.org](oncomine.org)), a gene expression array database used for the analysis of the transcription levels of genes in several types of cancer. The datasets used in the present study included Garber Lung Statistics ([@b25-ol-0-0-10905]), Okayama Lung Statistics ([@b26-ol-0-0-10905]), Bhattacharjee Lung Statistics ([@b27-ol-0-0-10905]), Hou Lung Statistics ([@b28-ol-0-0-10905]), Selamat Lung Statistics ([@b29-ol-0-0-10905]) and Landi Lung Statistics ([@b30-ol-0-0-10905]). P\<0.01 and a 1.5-fold change was set as the threshold. Genes in the present study were not limited by their rank. The final datasets collected are presented in [Table I](#tI-ol-0-0-10905){ref-type="table"}.

Data on the methylation status of BEX family was downloaded from MethHC ([methhc.mbc.nctu.edu.tw/](methhc.mbc.nctu.edu.tw/)), a database of DNA methylation status and gene expression in human cancer. Data on 464 tissue samples, 435 LUAD tissues and 29 normal tissues from healthy controls, with methylation values were obtained.

Mutational and copy number variations (CNVs) analyses of the BEX family members in LUAD samples were performed using cBioPortal for Cancer Genomics ([cbioportal.org/](cbioportal.org/)) as described previously ([@b31-ol-0-0-10905]). Data from the following studies were included: Lung Adenocarcinoma (Broad, Cell 2012) ([@b32-ol-0-0-10905]), Lung Adenocarcinoma (TCGA, Nature 2014) ([@b33-ol-0-0-10905]), Lung Adenocarcinoma (TCGA, Provisional) and Lung Adenocarcinoma (TCGA, PanCancer Atlas) ([@b34-ol-0-0-10905]).

### Cell lines and culture

Human bronchial epithelial (HBE) cells and the lung cancer cell lines H520, H1975, H358, H460, A549, 95D and SPC-A-1 were obtained from the Cell Bank of the Chinese Academy of Science. HBE cells were maintained in DMEM (HyClone) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and the lung cancer cell lines were cultured in RPMI-1640 medium (HyClone) supplemented with 10% FBS. All cells were maintained at 37°C with 5% CO~2~.

### RNA extraction and reverse-transcription quantitative polymerase chain reaction (RT-qPCR)

RNA extraction and RT-qPCR were performed as previously described ([@b35-ol-0-0-10905],[@b36-ol-0-0-10905]). The primers used in the present study are presented in [Table SI](#SD1-ol-0-0-10905){ref-type="supplementary-material"}.

### Receiver operating characteristic (ROC) curve analysis

The diagnostic value of the expression levels of the BEX family in LUAD was investigated by analyzing the expression data from 515 LUAD and 59 normal tissues. Specificity and sensitivity were plotted on the x- and y-axes, respectively. The area under curve (AUC) was calculated to assess the ability of the expression levels of BEX members to predict the outcome of patients with LUAD.

### Survival analysis

The association between expression of the BEX family members and the overall survival (OS) of patients with LUAD was assessed using a log-rank test and Kaplan-Meier analysis. The median expression value of each gene was used as the cut-off value to divide patients into high- and low-expression groups. The multivariate Cox regression model was applied for prognostic analysis.

### Statistical analysis

A two-tailed paired t-test with a Bonferroni\'s correction was used to analyze the gene expression differences in tumor and adjacent non-cancerous tissues. The Mann Whitney U test was used to compare tumor samples and unpaired normal control samples. The associations between the expression levels of BEX members and patient clinical characteristics were determined using a χ^2^ test. One-way ANOVA followed by the Dunnett\'s multiple comparisons test was used to analyze the expression level of BEX members in HBE cells compared with lung cancer cell lines. SPSS software (version 20; IBM Corp.) was used to perform all the statistical analysis. P\<0.05 was used to indicate a statistically significant difference.

Results
=======

### Expression level of BEX members is significantly downregulated in LUAD samples and tumor cell lines

The expression level of each BEX member was significantly downregulated in 59 LUAD tissues compared with the paired adjacent non-cancerous tissues (P\<0.01; [Fig. 1A-E](#f1-ol-0-0-10905){ref-type="fig"}). Similarly, the expression level of BEX members was significantly downregulated in the remaining 515 tumor samples compared with the unpaired normal control samples (P\<0.001; [Fig. S1A-E](#SD1-ol-0-0-10905){ref-type="supplementary-material"}). As presented in [Table I](#tI-ol-0-0-10905){ref-type="table"}, the expression results were successfully validated in independent cohorts from the Oncomine database. RT-qPCR revealed that the mRNA levels of BEX members were significantly decreased in the majority of the tumor cell lines, particularly in H1975, H358, SPC-A-1 and H520, compared with the HBE cells ([Fig. 2A-E](#f2-ol-0-0-10905){ref-type="fig"}).

### ROC analysis of BEX expression in patients with LUAD

Since the BEX family was significantly downregulated in LUAD samples compared with controls, the current study explored whether BEX members may serve as potential diagnostic biomarkers in LUAD. ROC curves and AUC analysis were performed to evaluate the overall prognostic performance. BEX1 \[AUC, 0.866; 95% CI (confidence interval), 0.837--0.895\], BEX2 (AUC, 0.629; 95% CI, 0.584--0.674), BEX3 (AUC, 0.732; 95% CI, 0.690--0.773), BEX4 (AUC, 0.886; 95% CI, 0.859--0.912) and BEX5 (AUC, 0.820; 95% CI, 0.779--0.860) had high sensitivity and specificity, suggesting that the BEX family may have diagnostic value in patients with LUAD ([Fig. 3A-E](#f3-ol-0-0-10905){ref-type="fig"}).

### Associations between the expression of the BEX family and clinicopathological characteristics of patients with LUAD

The associations between the expression levels of BEX members and the clinicopathological characteristics of 482 patients with LUAD were investigated. Low expression levels of BEX4 and BEX5 were significantly associated with an advanced American Joint Committee on Cancer (AJCC) clinical stage (P=0.004 and P=0.027, respectively; [Tables II](#tII-ol-0-0-10905){ref-type="table"} and [III](#tIII-ol-0-0-10905){ref-type="table"}, respectively) and advanced pathological T stage (P=0.002 and P=0.003, respectively; [Tables II](#tII-ol-0-0-10905){ref-type="table"} and [III](#tIII-ol-0-0-10905){ref-type="table"}, respectively). Lower expression level of BEX4 was significantly associated with pathological N stage (P=0.033, [Table II](#tII-ol-0-0-10905){ref-type="table"}). Decreased mRNA levels of BEX1 was significantly associated with advanced pathological T stage (P=0.023; [Tables SII](#SD1-ol-0-0-10905){ref-type="supplementary-material"}). The expression level of BEX2 and BEX4 was strongly associated with sex (P=0.003; P=0.005, respectively; [Tables SIII](#SD1-ol-0-0-10905){ref-type="supplementary-material"} and [II](#SD1-ol-0-0-10905){ref-type="supplementary-material"}, respectively). The expression level of BEX4 was significantly associated with age (P=0.019; [Table II](#tII-ol-0-0-10905){ref-type="table"}). There was no significant association between the expression of BEX3 and any clinicopathological characteristic in patients with LUAD ([Table SIV](#SD1-ol-0-0-10905){ref-type="supplementary-material"}).

### Prognostic value of the BEX family in patients with LUAD

The Kaplan-Meier method was used to assess the prognostic significance of the BEX family in patients with LUAD in the TCGA database. The expression levels of BEX1-3 were not significantly associated with OS ([Fig. 4A-C](#f4-ol-0-0-10905){ref-type="fig"}). However, the downregulation of BEX4 and BEX5 expression levels were significantly associated with poor OS (P\<0.001 and P=0.001, respectively; [Fig. 4D-E](#f4-ol-0-0-10905){ref-type="fig"}). The association between the expression levels of the BEX family and the outcomes of patients with LUAD using clinical stage subgroup analysis revealed that BEX4 and BEX5 were associated with the OS of patients with stage I--II (P\<0.001 and P=0.018, respectively; [Fig. S2D-E](#SD1-ol-0-0-10905){ref-type="supplementary-material"}), but not of patients with stage III--IV (P=0.261 and P=0.140, respectively; [Fig. S3D-E](#SD1-ol-0-0-10905){ref-type="supplementary-material"}). There was no significant difference between BEX1, BEX2 or BEX3 expression and OS of patients with stage I--II or stage III--IV ([Figs. S2A-C](#SD1-ol-0-0-10905){ref-type="supplementary-material"} and [3A-C](#SD1-ol-0-0-10905){ref-type="supplementary-material"}).

Characteristics such as age, sex, AJCC stage and the expression level of BEX members were analyzed using a multivariate Cox regression model. In addition to clinical stage \[hazard ratio (HR)=2.290; P\<0.001\], the expression level of the BEX family was an independent prognostic factor (HR=1.468 and P=0.030 for BEX3; HR=0.469 and P\<0.001 for BEX4; HR=0.723 and P=0.043 for BEX5) for patients with LUAD ([Table IV](#tIV-ol-0-0-10905){ref-type="table"}). In addition, as shown in [Table IV](#tIV-ol-0-0-10905){ref-type="table"}, BEX4 expression was significantly associated with OS at stages I--II (HR=0.476; P=0.002), while BEX3 (HR=2.450 and P=0.014), BEX4 (HR=0.288; P=0.001) and BEX5 (HR=0.569 and P=0.047) were associated with OS at stages III--IV.

### Methylation, mutation and CNV analysis of BEX family members in patients with LUAD

The total alteration frequency of gene mutations, amplifications and deletions in patients with LUAD was \<2% ([Fig. S4](#SD1-ol-0-0-10905){ref-type="supplementary-material"}) according to the sequencing data in datasets obtained from cBioPortal. BEX1 and BEX3 were hypermethylated in tumor tissues compared with normal tissues, whereas BEX2, BEX4 and BEX5 did not exhibit any statistically significant difference in methylation ([Fig. S5](#SD1-ol-0-0-10905){ref-type="supplementary-material"}).

Discussion
==========

Despite improvement in diagnostic and treatment strategies, the prognosis of patients with lung cancer remains poor ([@b37-ol-0-0-10905]), potentially due to a lack of effective predictive markers at the early stages of the disease ([@b38-ol-0-0-10905],[@b39-ol-0-0-10905]). Therefore, novel biomarkers for the detection and prognosis evaluation of LUAD are required. Previous studies have revealed that the BEX family may serve roles as predictive biomarkers in tumors, such as esophageal squamous cell cancer and acute myeloid leukemia ([@b12-ol-0-0-10905],[@b40-ol-0-0-10905]). The potential clinical value of the BEX family members in LUAD warrants further research.

The present study aimed to investigate the role of the BEX family in LUAD. The expression levels of BEX1-5 in LUAD were examined by mining the TCGA and Oncomine databases. The results obtained in the current study revealed that the expression levels of BEX members in carcinoma tissues were significantly decreased compared with normal tissues. Similarly, experimental *in vitro* data revealed that the mRNA levels of BEX members were decreased in the majority of the lung cancer cell lines investigated compared with HBE cells. The abnormal expression of the BEX family has been implicated in various types of cancer, such as breast cancer and oral squamous cell carcinoma ([@b16-ol-0-0-10905],[@b20-ol-0-0-10905]). The expression levels of BEX1 and BEX4 were significantly reduced in oral squamous cell carcinoma tissues compared with paired normal epithelial ([@b20-ol-0-0-10905]). Foltz *et al* ([@b41-ol-0-0-10905]) reported that BEX1 and BEX2 had differentially methylated CpG sites and increased methylation was associated with a decreased expression level in malignant glioma tissues compared with paired normal specimens. Previous studies revealed that several factors are involved in gene regulation, including mutations, copy number variations (CNVs) and DNA methylation ([@b42-ol-0-0-10905]--[@b46-ol-0-0-10905]). To further explore the results of differential expression, gene methylation status, mutation status and CNVs were analyzed. As the total alteration frequency of gene mutations, amplifications and deletions was \<2%, the expression levels of the BEX family were likely not associated with mutations or CNVs. The methylation status of BEX1 and BEX3 may partially explain the low expression of them in LUAD. However, the mechanisms underlying the downregulation of BEX family requires further investigation.

Gene expression signatures have been used for the clinical diagnosis of various types of cancer ([@b47-ol-0-0-10905]). The differential expression of the BEX family in LUAD and normal tissues revealed in the present study suggested that that the BEX family may have diagnostic value in LUAD. Furthermore, the high AUC values obtained in the present study indicated that BEX1-5 exhibited good diagnostic performance. Whether the combination of BEX members provides higher sensitivity and specificity compared the individual use of each BEX family member requires further investigation.

A previous study reported that low expression of BEX1 was associated with clinicopathological characteristics such as tumor volume, T stage and clinical stage in esophageal squamous cell cancer ([@b12-ol-0-0-10905]). The present study investigated the association between the expression of the BEX family and the clinicopathological features of patients with LUAD. The low expression levels of BEX1, BEX4 and BEX5 were significantly associated with advanced clinical stage. The downregulation of BEX4 was significantly associated with regional lymph node metastasis. These results suggested the BEX family may be involved in tumor invasion and metastasis, which may result in less favorable outcomes in patients with LUAD. Additional studies are required to investigate the effect of the BEX family on tumor metastasis.

The present study revealed that BEX4 and BEX5 were associated with the prognosis of LUAD patients. The low expression levels of BEX4 and BEX5 were associated with poor prognosis. The results obtained in the current study suggested that members of the BEX family may serve as biomarkers for predicting poor prognosis in patients with LUAD.

The present study is limited by the lack of sufficient experimental data and validation at the protein level. Therefore, further studies using large, independent clinical cancer cohorts are required to corroborate the results obtained in the present study. Additionally, the roles and underlying mechanisms of members of the BEX family in the development of LUAD remain unclear and warrant further investigation. In summary, the present study demonstrated that the BEX family was significantly downregulated in LUAD tissues compared with normal tissues, and that this expression pattern may serve as a potential biomarker for the diagnosis and prognosis prediction of patients with LUAD.
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![Expression of (A) BEX1, (B) BEX2, (C) BEX3, (D) BEX4 and (E) BEX5 was significantly downregulated in lung adenocarcinoma compared with healthy adjacent non-cancerous samples obtained from The Cancer Genome Atlas. Data were analyzed using the two-tailed paired t-test, with BEX, brain-expressed X-linked.](ol-18-05-5523-g00){#f1-ol-0-0-10905}

![Expression levels of the BEX family were significantly downregulated in the majority of the lung adenocarcinoma cell lines investigated. The mRNA expression of (A) BEX1, (B) BEX2, (C) BEX3, (D) BEX4 and (E) BEX5 in HBE, H520, H1975, H358, H460, A549, 95D and SPC-A-1 cells was determined using reverse-transcription quantitative polymerase chain reaction. \*P\<0.05 and \*\*P\<0.01 vs. HBE cells. BEX, brain-expressed X-linked; HBE, human bronchial epithelial.](ol-18-05-5523-g01){#f2-ol-0-0-10905}

![Receiver operating characteristic curves for estimating the diagnostic value of (A) BEX1, (B) BEX2, (C) BEX3, (D) BEX4 and (E) BEX5. The red and black lines represent the ROC curves of BEX family and the random performance, respectively. BEX, brain-expressed X-linked; AUC, area under the curve.](ol-18-05-5523-g02){#f3-ol-0-0-10905}

![Kaplan-Meier survival curves for assessing the prognostic value of (A) BEX1, (B) BEX2, (C) BEX3, (D) BEX4 and (E) BEX5 in 482 patients with lung adenocarcinoma. BEX, brain-expressed X-linked.](ol-18-05-5523-g03){#f4-ol-0-0-10905}

###### 

Changes in the BEX family transcription levels between lung adenocarcinoma and normal tissues obtained from the ONCOMINE database.

  A, BEX1                                                      
  -------------- ----------------- -------------- ------------ -------------------------------
  218332_at      −3.869            1.53×10^−11^   −10.401      Okayama lung statistics
  IMAGE:341706   −1.502            0.003          −3.193       Garber lung statistics
  ILMN_2234697   −1.941            1.22×10^−10^   −7.024       Selamat lung statistics
                                                               
  **B, BEX2**                                                  
                                                               
  **Reporter**   **Fold change**   **P-value**    **t-test**   **Oncomine dataset**
                                                               
  224367_at      −1.723            2.39×10^−4^    −3.727       Hou lung statistics
                                                               
  **C, BEX3**                                                  
                                                               
  **Reporter**   **Fold change**   **P-value**    **t-test**   **Oncomine dataset**
                                                               
  ILMN_1729208   −1.508            2.02×10^−5^    −4.276       Selamat lung statistics
                                                               
  **D, BEX4**                                                  
                                                               
  **Reporter**   **Fold change**   **P-value**    **t-test**   **Oncomine dataset**
                                                               
  40916_at       −3.440            4.62×10^−5^    −4.828       Bhattacharjee lung statistics
  ILMN_2351638   −2.339            3.68×10^−17^   −9.910       Selamat lung statistics
  215440_s\_at   −1.756            1.55×10^−9^    −6.562       Landi lung statistics
  215440_s\_at   −1.960            4.20×10^−7^    −5.594       Hou lung statistics
                                                               
  **E, BEX5**                                                  
                                                               
  **Reporter**   **Fold change**   **P-value**    **t-test**   **Oncomine dataset**
                                                               
  ILMN_1806473   −1.624            1.82×10^−11^   −7.327       Selamat lung statistics
  229963_at      −1.868            1.33×10^−4^    −3.885       Hou lung statistics

Threshold, P\<0.01, fold change 1.5 and under-expression.

###### 

Association between the BEX4 expression level and patient clinical characteristics in The Cancer Genome Atlas lung adenocarcinoma cohort.

                                   BEX4 expression                  
  -------------------------- ----- ----------------- ----- -------- -------
  Age at diagnosis (years)                                 5.545    0.019
    \<60                     131   54                77             
    ≥60                      351   187               164            
  Sex                                                      8.030    0.005
    Male                     221   95                126            
    Female                   261   146               115            
  Clinical stage                                           8.288    0.004
    I+II                     378   202               176            
    III+IV                   104   39                65             
  T (Primary tumor)                                        15.226   0.002
    T1                       165   101               64             
    T2                       252   116               136            
    T3                       44    15                29             
    T4                       18    7                 11             
    TX                       3     2                 1              
  N (Regional lymph nodes)                                 4.549    0.033
    N0                       312   166               146            
    N1-3                     161   69                92             
    NX                       9     6                 3              
  M (Distant metastases)                                   0.552    0.457
    M0                       319   158               161            
    M1                       24    10                14             
    MX                       139   73                66             

A total of 482 samples were analyzed, 241 with low BEX4 expression and 241 with high BEX4 expression. A χ^2^ test was used for statistical analysis. BEX, brain-expressed X-linked.

###### 

Associations between the BEX5 expression level and patient clinical characteristics in The Cancer Genome Atlas lung adenocarcinoma cohort.

                                   BEX5 expression                  
  -------------------------- ----- ----------------- ----- -------- -------
  Age at diagnosis (years)                                 1.268    0.260
    \<60                     131   60                71             
    ≥60                      351   181               170            
  Sex                                                      3.017    0.082
    Male                     221   101               120            
    Female                   261   140               121            
  Clinical stage                                           4.904    0.027
    I+II                     378   199               179            
    III+IV                   104   42                62             
  T (Primary tumor)                                        14.117   0.003
    T1                       165   102               63             
    T2                       252   109               143            
    T3                       44    21                23             
    T4                       18    8                 10             
    TX                       3     1                 2              
  N (Regional lymph nodes)                                 2.204    0.138
    N0                       312   162               150            
    N1-3                     161   72                89             
    NX                       9     7                 2              
  M (Distant metastases)                                   0.041    0.840
    M0                       319   153               166            
    M1                       24    11                13             
    MX                       139   77                62             

A total of 482 samples were analyzed, 241 with low BEX5 expression and 241 with high BEX5 expression. A χ^2^ test was used for statistical analysis. BEX, brain-expressed X-linked.

###### 

Multivariate analyses of overall survival in patients with lung adenocarcinoma.

  A, All patients                                                                    
  ----------------------------------- --------------------------- ------------------ -----------------------------
  Age (≥60 vs.\<60)                   0.549                       1.108              0.792--1.549
  Sex (female vs. male)               0.543                       1.081              0.797--1.466
  Clinical stage (III/IV vs. I/II)    \<0.001                     2.290              1.665--3.149
  BEX1 expression (high vs. low)      0.394                       1.146              0.838--1.567
  BEX2 expression (high vs. low)      0.452                       1.167              0.781--1.745
  BEX3 expression (high vs. low)      0.030                       1.468              1.038--2.077
  BEX4 expression (high vs. low)      \<0.001                     0.469              0.320--0.686
  BEX5 expression (high vs. low)      0.043                       0.723              0.528--0.989
                                                                                     
  **B, Patients with stage I+II**                                                    
                                                                                     
                                      **Multivariate analysis**                      
                                                                                     
  **Parameter**                       **P-value**                 **Hazard ratio**   **95% confidence interval**
                                                                                     
  Age (≥60 vs. \<60)                  0.216                       1.321              0.850--2.051
  Sex (female vs. male)               0.912                       0.979              0.675--1.421
  BEX1 expression (high vs. low)      0.519                       1.134              0.773--1.664
  BEX2 expression (high vs. low)      0.915                       0.974              0.604--1.572
  BEX3 expression (high vs. low)      0.341                       1.220              0.810--1.835
  BEX4 expression (high vs. low)      0.002                       0.476              0.299--0.757
  BEX5 expression (high vs. low)      0.265                       0.798              0.537--1.186
                                                                                     
  **C, Patients with stage III+IV**                                                  
                                                                                     
                                      **Multivariate analysis**                      
                                                                                     
  **Parameter**                       **P-value**                 **Hazard ratio**   **95% confidence interval**
                                                                                     
  Age (≥60 vs.\<60)                   0.892                       1.040              0.592--1.827
  Sex (female vs. male)               0.126                       1.587              0.878--2.869
  BEX1 expression (high vs. low)      0.662                       1.139              0.635--2.042
  BEX2 expression (high vs. low)      0.173                       1.696              0.793--3.628
  BEX3 expression (high vs. low)      0.014                       2.450              1.197--5.015
  BEX4 expression (high vs. low)      0.001                       0.288              0.134--0.618
  BEX5 expression (high vs. low)      0.047                       0.569              0.326--0.992

BEX, brain-expressed X-linked.
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